title: [Are antiangiogenic antibodies universal for solid tumor?].
abstract: After over 30 years of theorizing, the use of angiogenesis inhibitors as anticancer therapy has finally moved from the realm of research to reality. Normal adult vasculature is generally quiescent in nature, with endothelial cells dividing approximately every 10 years. In contrast, the growth of tumours requires constant vascular growth and remodelling in order for solid tumours to grow beyond 1-2 mm3 in size. Vascular endothelial growth factor (VEGF) and its receptors are key regulators of the process of angiogenesis, which make them attractive therapeutic targets. A multitude of VEGF-targeted inhibitory agents are currently being investigated for the treatment of cancer. This review article focuses on recent developments in the use of angiogenesis inhibitors for the treatment of breast, lung, and colorectal cancers.
authors.affiliation: Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon. ray@lyon.fnclcc.fr
authors.forename: Isabelle
authors.initials: I
authors.lastname: Ray-Coquard
authors.forename: Thomas
authors.initials: T
authors.lastname: Bachelot
authors.forename: Chadi
authors.initials: C
authors.lastname: Saba
authors.forename: Cyrille
authors.initials: C
authors.lastname: Confavreux
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Brantus
authors.forename: Fadi
authors.initials: F
authors.lastname: Rustam
authors.forename: Hervé
authors.initials: H
authors.lastname: Ghesquière
authors.forename: Catherine
authors.initials: C
authors.lastname: Sebban
authors.forename: Pierre
authors.initials: P
authors.lastname: Biron
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Guastalla
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000188:drug therapy; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000188:drug therapy; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000276:immunology; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin